Impact of new TKIs on NSCLC treatment planning

Impact of new TKIs on NSCLC treatment planning

VJOncology

1 year
158 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Several generations of tyrosine kinase inhibitors (TKIs) have now been produced and examined for the treatment of EGFR mutant non-small cell lung cancer (NSCLC). Here, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses the different TKI treatment options at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland. He explores the varied benefits of gefitinib, erlotinib, afatinib and osimertinib, as well as the results of the FLAURA trial (NCT02296125), and the implications of these data on treatment sequencing.
Up Next Autoplay